Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/02/2020 04/03/2020 04/06/2020 04/07/2020 04/08/2020 Date
208.88(c) 205.41(c) 211.58(c) 208.78(c) 219.19(c) Last
3 867 332 2 281 426 3 702 502 2 447 461 2 861 876 Volume
+5.60% -1.66% +3.00% -1.32% +4.99% Change
More quotes
Financials (USD)
Sales 2020 25 543 M
EBIT 2020 11 911 M
Net income 2020 7 222 M
Debt 2020 19 755 M
Yield 2020 2,90%
Sales 2021 26 363 M
EBIT 2021 12 390 M
Net income 2021 8 178 M
Debt 2021 16 522 M
Yield 2021 3,11%
P/E ratio 2020 17,6x
P/E ratio 2021 15,3x
EV / Sales2020 5,82x
EV / Sales2021 5,51x
Capitalization 129 B
More Financials
Company
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc. The United States account for 74.5% of net sales; - other (5%):... 
Sector
Pharmaceuticals
Calendar
04/28Earnings Release
More about the company
Surperformance© ratings of Amgen Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN INC.
04/07AMGEN : Can Therapeutic Antibodies Offer Hope for COVID-19 Patients?
PU
04/07AMGEN : And Adaptive Biotechnologies To Participate In Webinar On COVID-19 Strat..
PR
04/02AMGEN : And Adaptive Biotechnologies Announce Strategic Partnership To Develop A..
PR
03/31AMGEN : Establishes Wholly-Owned Affiliate In Japan
PR
03/31AMGEN : 2019 Letter to Shareholders
PU
03/31AMGEN : Update Regarding COVID-19 For Media
PU
03/31AMGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
03/23AMGEN : Update Regarding COVID-19 For Media
PU
03/23AMGEN : And The Amgen : Foundation Commit Up To $12.5 Million To Support COVID-1..
PR
03/20AMGEN : R&D Head Dr. David Reese Shares Perspective on COVID-19
PU
03/17AMGEN : Update Regarding COVID-19 For Media
PU
03/16Pharmaceutical Firms Curtailing In-Person Sales Calls to Doctors
DJ
03/16Pharmaceutical Firms Curtailing In-Person Sales Calls to Doctors
DJ
03/13AMGEN : Update Regarding COVID-19
PU
03/11AMGEN : Update Regarding COVID-19
PU
More news
News in other languages on AMGEN INC.
03/11STRATÉGIE : des actions pour miser sur l'économie circulaire
02/26Wall-Street : le rebond avorte, le pétrole rechute de -2,5%
02/13AMGEN : Ex-dividend day for
02/06Molecular Partners steigert 2019 Umsatz aber schreibt weiter Verlust
01/31DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 31.01.2020 - 15.15 Uhr
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 243,15  $
Last Close Price 219,19  $
Spread / Highest target 30,0%
Spread / Average Target 10,9%
Spread / Lowest Target -15,6%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-9.08%128 832
JOHNSON & JOHNSON-5.75%362 446
ROCHE HOLDING AG0.67%277 253
MERCK & CO., INC-10.26%198 371
NOVARTIS-9.90%193 214
PFIZER, INC.-11.69%186 456